Cheung Angela C, Lazaridis Konstantinos N, LaRusso Nicholas F, Gores Gregory J
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Curr Opin Gastroenterol. 2017 May;33(3):149-157. doi: 10.1097/MOG.0000000000000352.
The only currently approved treatment for primary sclerosing cholangitis (PSC) is liver transplantation, with a median time to transplant of 12-18 years after diagnosis. There are a number of emerging drugs that have the potential to meet this critically unmet need that will be summarized and discussed herein.
Although the cause of PSC is unknown, there are a number of novel therapeutics under development. These drugs target presumed pathogenic mechanisms largely extrapolated from ex-vivo and in-vivo preclinical models, as well as translational observations.
Future therapeutic strategies for PSC may include a multitude of complex pathogenic mechanisms encompassing pathways of immunomodulation, the microbiome and inflammation-related fibrosis.
目前唯一被批准用于原发性硬化性胆管炎（PSC）的治疗方法是肝移植，诊断后至移植的中位时间为12至18年。有多种新兴药物有潜力满足这一迫切未被满足的需求，本文将对其进行总结和讨论。
尽管PSC的病因尚不清楚，但有多种新型治疗方法正在研发中。这些药物主要针对从体外和体内临床前模型以及转化观察中推断出的假定致病机制。
PSC未来的治疗策略可能包括多种复杂的致病机制，涵盖免疫调节、微生物群和炎症相关纤维化等途径。
